-
Dienstag J L, Schiff E R, Wright T L. Lamivudine as initial treatment for chronic hepatitis b in the united states[J]. N Engl J Med, 1999, 341(17): 1256-1263. doi: 10.1056/NEJM199910213411702
-
Ferreira R, Carvalheiro J, Torres J. Fatal hepatitis b reactivation treated with entecavir in an isolated anti-hbs positive lymphoma patient: A case report and literature review[J]. Saudi J Gastroenterol, 2012, 18(4): 277-281. doi: 10.4103/1319-3767.98436
-
Fukushima N, Mizuta T, Tanaka M. Retrospective and prospective studies of hepatitis b virus reactivation in malignant lymphoma with occult hbv carrier[J]. Ann Oncol, 2009, 20(12): 2013-2017. doi: 10.1093/annonc/mdp230
-
Kim I K, Kim B G, Kim W. Clinical prediction of failure of lamivudine prophylaxis for patients with hepatitis b infection undergoing cytotoxic chemotherapy for malignancy[J]. Antimicrob Agents Chemother, 2012, 56(11): 5511-5519. doi: 10.1128/AAC.00821-12
-
Kondili L A, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis b (a series of cases)[J]. J Viral Hepat, 2004, 11(5): 427-431. doi: 10.1111/jvh.2004.11.issue-5
-
Lai C L, Chien R N, Leung N W. A one-year trial of lamivudine for chronic hepatitis b. Asia hepatitis lamivudine study group[J]. N Engl J Med, 1998, 339(2): 61-68. doi: 10.1056/NEJM199807093390201
-
Lee I C, Huang Y H, Chu C J. Hepatitis b virus reactivation after 23 months of rituximab-based chemotherapy in an hbsag-negative, anti-hbs-positive patient with follicular lymphoma[J]. J Chin Med Assoc, 2010, 73(3): 156-160. doi: 10.1016/S1726-4901(10)70031-9
-
Lu M, Lorentz T. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis b virus despite the presence of protective anti-hepatitis b surface antibody[J]. J Infect Dis, 2003, 187(8): 1323-1326. doi: 10.1086/jid.2003.187.issue-8
-
Matsue K, Kimura S, Takanashi Y. Reactivation of hepatitis b virus after rituximab-containing treatment in patients with cd20-positive b-cell lymphoma[J]. Cancer, 2010, 116(20): 4769-4776. doi: 10.1002/cncr.v116:20
-
Miyake Y, Iwasaki Y, Takaki A. Lamivudine treatment improves the prognosis of fulminant hepatitis b[J]. Intern Med, 2008, 47(14): 1293-1299. doi: 10.2169/internalmedicine.47.1061
-
Norder H, Couroucé A M, Coursaget P. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes[J]. Intervirology, 2004, 47(6): 289-309. doi: 10.1159/000080872
-
Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E. Lamivudine treatment for acute severe hepatitis b: A pilot study[J]. Liver Int, 2004, 24(6): 547-551. doi: 10.1111/liv.2004.24.issue-6
-
Tillmann H L, Hadem J, Leifeld L. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis b, a multicenter experience[J]. J Viral Hepat, 2006, 13(4): 256-263. doi: 10.1111/jvh.2006.13.issue-4
-
Yeo W, Chan T C, Leung N W. Hepatitis b virus reactivation in lymphoma patients with prior resolved hepatitis b undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol, 2009, 27(4): 605-611. doi: 10.1200/JCO.2008.18.0182
-
Yuen M F, Sablon E, Hui C K. Factors associated with hepatitis b virus DNA breakthrough in patients receiving prolonged lamivudine therapy[J]. Hepatology, 2001, 34(4 Pt 1): 785-791.